samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

Biognosys

The new and improved workflow will offer unprecedented depth and quantitative precision, identifying up to 3,000 plasma proteins


October 5th, 2021 – SCHLIEREN, (Zurich, Switzerland).
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.

The launch will feature a:
The biomarker discovery solution will be offered as a contract research service, designed to help biopharma and academic researchers decode the complexity of biology and unlock true, unbiased discoveries for drug development.

The new and improved workflow will offer unprecedented depth and quantitative precision. The workflow will search the complete plasma proteome to identify up to 3,000 of the most relevant plasma proteins. Measuring on average ten peptides for each identified protein, the research service will provide the deepest ever understanding of the key pathways involved in discovery research.

The workflow can be applied across all biological species and to other biofluids, such as cerebrospinal fluid (CSF) or urine. In addition to the biofluid biomarker discovery service, an improved tissue biomarker discovery service will become available, offering an industry-leading depth of 10,000 proteins.

Both solutions will be based on Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and the latest, optimized LC-MS workflow.
phone +41 44 738 20 40
email info@biognosys.com
web biognosys.com
email Wagistrasse 21, 8952 Schlieren, Switzerland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>


White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement